成人风湿免疫病患者新型冠状病毒疫苗接种及风险防控中国专家共识(2023版)  

Expert consensus on SARS-CoV-2 vaccination, risk prevention and control in adult patients with rheumatic and immune diseases in China(2023)

作　　者：郑文洁[1] 张卓莉[2] 何岚[3] 李芬[4] 穆荣 魏蔚[6] 武丽君[7] 谢其冰[8] 杨念生[9] 杨娉婷[10] 张文[1] 董凌莉[11] 赵岩[1] 中国初级卫生保健基金会风湿免疫学专业委员会 中华医学会风湿病学分会 Zheng Wenjie;Zhang Zhuoli;He Lan;Li Fen;Mu Rong;Wei Wei;Wu Lijun;Xie Qibing;Yang Niansheng;Yang Pingting;Zhang Wen;Dong Lingli;Zhao Yan;on behalf of Rheumatological Immunology Committee of China Primary Health Care Foundation;Chinese Rheumatology Association(Department of Rheumatology and Clinical Immunology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,National Clinical Research Center for Dermatologic and Immunologic Diseases,Ministry of Science&Technology,State Key Laboratory of Complex Severe and Rare Diseases,Key Laboratory of Rheumatology and Clinical Immunology,Ministry of Education,Beijing 100730,China;Department of Rheumatology,Peking University First Hospital,Beijing 100034,China;Department of Rheumatology,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;Department of Rheumatology,the Second Hospital of Xiangya,Central South University,Changsha 410011,China;Department of Rheumatology,Peking University Third Hospital,Beijing 100191,China;Department of Rheumatology,Tianjin Medical University General Hospital,Tianjin 300052,China;Department of Rheumatology,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China;Department of Rheumatology,West China Hospital,Sichuan University,Chengdu 610000,China;Department of Rheumatology,First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China;Department of Rheumatology,the First Hospital of China Medical University,Shenyang 110000,China;Department of Rheumatology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;不详)

机构地区：[1]中国医学科学院北京协和医学院,北京协和医院风湿免疫科,北京100730 [2]北京大学第一医院风湿免疫科,北京100034 [3]西安交通大学第一附属医院风湿免疫科,西安710061 [4]中南大学湘雅二医院风湿免疫科,长沙410011 [5]北京大学第三医院风湿免疫科,北京100191 [6]天津医科大学总医院风湿免疫科,天津300052 [7]新疆维吾尔自治区人民医院风湿免疫科,乌鲁木齐830001 [8]四川大学华西医院风湿免疫科,成都610000 [9]中山大学附属第一医院风湿免疫科,广州510080 [10]中国医科大学附属第一医院风湿免疫科,沈阳110001 [11]华中科技大学同济医学院附属同济医院风湿免疫科,武汉430030 [12]不详

出　　处：《中华风湿病学杂志》2023年第10期649-658,共10页Chinese Journal of Rheumatology

摘　　要：新型冠状病毒感染从2019年年底以来席卷全球, 给人类健康带来危害, 疫苗接种是预防新型冠状病毒感染和降低感染后重症化的有效手段。加快新型冠状病毒疫苗接种速度、扩大接种范围、提高全人群疫苗接种率已成为国际社会防控新型冠状病毒蔓延的共识。风湿免疫病患者是罹患新型冠状病毒感染的高危人群, 该群体因疾病本身和长期用药往往处于免疫功能紊乱状态, 存在新型冠状病毒疫苗类型选择、使用方法、免疫应答减弱、突破性感染等一系列问题。本文基于国内外最新循证医学证据, 就成人风湿免疫病患者接种新型冠状病毒疫苗与新型冠状病毒预防的相关问题提出建议并形成专家共识, 以供临床医生及卫生保健人员参考。

关 键 词：风湿免疫病 冠状病毒感染 疫苗接种 单克隆抗体 

分 类 号：R593.2[医药卫生—内科学] R186[医药卫生—临床医学]